The chemotherapy known as busulfan is more than six decades old, and part of doctors’ standard arsenal against leukemia. It’s not scarce, and by all accounts, it should be dirt cheap.
Category: Ovarian Cancer
3 Biotechs Likely to Be Acquired in 2017
The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.